Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN (AdiraMedica Pty Ltd)
Product name
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 (255 working days)
Active ingredients
pregabalin
Registration type
New generic medicine
Indication
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN (capsule) is indicated for the treatment of neuropathic pain in adults.
Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.